G&E Herbal Biotechnology Co., Ltd. (TPEX:4911)
Taiwan
· Delayed Price · Currency is TWD 47.75
-0.15 (-0.31%)
Dec 5, 2025, 1:02 PM CST
G&E Herbal Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 311.78 | 249.03 | 181.44 | 64.61 | 24.57 | 28.23 | Upgrade
|
| Revenue Growth (YoY) | 37.92% | 37.25% | 180.84% | 162.94% | -12.96% | 60.82% | Upgrade
|
| Cost of Revenue | 46.75 | 43.69 | 36.86 | 25.25 | 14.95 | 16.22 | Upgrade
|
| Gross Profit | 265.03 | 205.34 | 144.59 | 39.35 | 9.63 | 12.01 | Upgrade
|
| Selling, General & Admin | 72.83 | 50.36 | 39.3 | 19.48 | 16.65 | 14.77 | Upgrade
|
| Research & Development | 34.61 | 35.34 | 24.6 | 14.39 | 12.54 | 12.72 | Upgrade
|
| Operating Expenses | 107.44 | 85.7 | 63.9 | 33.87 | 29.19 | 27.49 | Upgrade
|
| Operating Income | 157.6 | 119.65 | 80.68 | 5.49 | -19.56 | -15.47 | Upgrade
|
| Interest Expense | -0.04 | -0.04 | -0 | - | - | - | Upgrade
|
| Interest & Investment Income | 6.16 | 4.48 | 4.4 | 0.6 | 0.52 | 0.61 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.4 | 0.03 | 0.01 | 1.06 | -0.39 | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.19 | 0.63 | 0.31 | 0.08 | 0 | 0.04 | Upgrade
|
| EBT Excluding Unusual Items | 163.51 | 124.74 | 85.4 | 7.23 | -19.43 | -14.84 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0 | -0.01 | -0.01 | -0 | -0.02 | -0.01 | Upgrade
|
| Legal Settlements | - | - | 5.12 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 1.22 | 1.79 | Upgrade
|
| Pretax Income | 163.51 | 124.73 | 90.5 | 7.23 | -18.22 | -13.06 | Upgrade
|
| Income Tax Expense | 20.41 | 22.67 | 18.1 | -0.15 | 1.66 | 1.24 | Upgrade
|
| Net Income | 143.1 | 102.06 | 72.4 | 7.38 | -19.88 | -14.3 | Upgrade
|
| Net Income to Common | 143.1 | 102.06 | 72.4 | 7.38 | -19.88 | -14.3 | Upgrade
|
| Net Income Growth | 60.36% | 40.97% | 880.90% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 64 | 64 | 64 | 64 | 64 | 64 | Upgrade
|
| Shares Outstanding (Diluted) | 64 | 64 | 64 | 64 | 64 | 64 | Upgrade
|
| Shares Change (YoY) | 0.05% | 0.06% | 0.08% | - | - | - | Upgrade
|
| EPS (Basic) | 2.25 | 1.60 | 1.14 | 0.12 | -0.31 | -0.22 | Upgrade
|
| EPS (Diluted) | 2.24 | 1.60 | 1.14 | 0.11 | -0.31 | -0.22 | Upgrade
|
| EPS Growth | 60.07% | 40.97% | 900.19% | - | - | - | Upgrade
|
| Free Cash Flow | 165.63 | 128.76 | 107.96 | 97.01 | -10.96 | -4.23 | Upgrade
|
| Free Cash Flow Per Share | 2.60 | 2.02 | 1.69 | 1.52 | -0.17 | -0.07 | Upgrade
|
| Dividend Per Share | 0.701 | 0.701 | 0.498 | - | - | - | Upgrade
|
| Dividend Growth | 40.75% | 40.75% | - | - | - | - | Upgrade
|
| Gross Margin | 85.01% | 82.46% | 79.69% | 60.91% | 39.17% | 42.56% | Upgrade
|
| Operating Margin | 50.55% | 48.04% | 44.47% | 8.49% | -79.61% | -54.81% | Upgrade
|
| Profit Margin | 45.90% | 40.98% | 39.90% | 11.42% | -80.92% | -50.66% | Upgrade
|
| Free Cash Flow Margin | 53.12% | 51.70% | 59.50% | 150.15% | -44.61% | -14.98% | Upgrade
|
| EBITDA | 167.26 | 129.24 | 89.9 | 14.89 | -10.23 | -6.26 | Upgrade
|
| EBITDA Margin | 53.65% | 51.90% | 49.55% | 23.04% | -41.62% | -22.19% | Upgrade
|
| D&A For EBITDA | 9.67 | 9.59 | 9.22 | 9.4 | 9.33 | 9.21 | Upgrade
|
| EBIT | 157.6 | 119.65 | 80.68 | 5.49 | -19.56 | -15.47 | Upgrade
|
| EBIT Margin | 50.55% | 48.04% | 44.47% | 8.49% | -79.61% | -54.81% | Upgrade
|
| Effective Tax Rate | 12.48% | 18.17% | 20.00% | - | - | - | Upgrade
|
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.